FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	Issuer Name and Ticker or Trading Symbol Denali Therapeutics Inc. [DNLI] Dete of Farliant Transaction (Month/Day/Year)										all app	ionship of Reporting all applicable) Director		10% Ov	vner				
(Last)	ist) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/28/2023								Officer (give title below)			Other (specify below)	
161 OYS	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person									
	OUTH SAN CA 94080														Form filed by More than One Reporting Person				
(City)	FRANCISCO GYY S4000 (City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is interest to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											tended			
		Table	l - N	on-Deriva	tive S	ecui	rities	Ac	quired,	, Dis	sposed of	f, or B	enefic	ially	Owr	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y						Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Disposed Of 5)					and Securi Benefi Owned Follow		cially I ing	Forr (D) (m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	Amount	(A) or (D)	Price		Report Transa (Instr.	rted action(s) 3 and 4)							
Common	Stock		23				S ⁽¹⁾		552	D	\$29.5	5 ⁽²⁾ 135,		35,817		D			
Common	Stock)23				S ⁽¹⁾		1,114	D	\$29.9	8(3)	134	134,703 ⁽⁴⁾		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expirat (Month	ion D		Ĺ	nt of ties ying tive ty 3 and 4)	Deri Secu	Price of ivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date		Amount or Number of Shares						

Explanation of Responses:

- 1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023.
- 2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$28.85 to \$29.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 3. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$29.85 to \$30.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 4. Includes 4,216 RSUs.

Remarks:

/s/ Alexander Schuth, by power of attorney

06/30/2023

** Signature of Reporting Person

n Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.